黏性纤维补充剂应纳入糖尿病管理:随机对照试验的系统评价与荟萃分析
该系统评价与荟萃分析纳入28项随机对照试验(n=1,394),评估黏性纤维对2型糖尿病血糖控制的影响。中位剂量约13.1 g/天的黏性纤维补充剂显著降低HbA1c、空腹血糖和HOMA-IR,证据确定性为中等。结论认为黏性纤维补充剂可改善血糖控制,应考虑用于2型糖尿病管理。
要点
- 黏性纤维补充剂中位剂量约13.1 g/天可显著降低2型糖尿病患者的HbA1c。
- 黏性纤维补充剂可显著降低空腹血糖和HOMA-IR,改善胰岛素抵抗。
- 黏性纤维补充剂应在常规治疗基础上考虑用于2型糖尿病管理。
核心结论
- 黏性纤维补充剂可改善2型糖尿病患者的血糖控制指标,应考虑纳入管理。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials至2018年6月15日。
- 纳入28项随机对照试验比较(n=1,394),干预时长≥3周,评估黏性纤维对2型糖尿病血糖控制指标的影响。
主要发现
- 与对照相比,黏性纤维中位剂量约13.1 g/天显著降低HbA1c(MD -0.58% [95% CI -0.88, -0.28];P=0.0002)。
- 黏性纤维显著降低空腹血糖(MD -0.82 mmol/L [95% CI -1.32, -0.31];P=0.001)。
- 黏性纤维显著降低HOMA-IR(MD -1.89 [95% CI -3.45, -0.33];P=0.02)。
关键数值与推荐
- HbA1c、空腹血糖、空腹胰岛素和HOMA-IR的证据确定性为中等,果糖胺为低。
临床怎么用
- 在常规治疗基础上,可考虑使用黏性纤维补充剂(中位剂量约13.1 g/天)以改善2型糖尿病患者的血糖控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evidence from randomized controlled trials (RCTs) suggests that viscous dietary fiber may offer beneficial effects on glycemic control and, thus, an improved cardiovascular disease risk profile. Our purpose was to conduct a systematic review and meta-analysis of RCTs to synthesize the therapeutic effect of viscous fiber supplementation on glycemic control in type 2 diabetes. RESEARCH DESIGN AND METHODS: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were searched through 15 June 2018. We included RCTs ≥3 weeks in duration that assessed the effects of viscous fiber on markers of glycemic control in type 2 diabetes. Two independent reviewers extracted data. Data were pooled using the generic inverse variance method and expressed as mean differences (MD) with 95% CIs. Heterogeneity was assessed (Cochran Q statistic) and quantified (I 2 statistic). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the overall certainty of the evidence. RESULTS: We identified 28 eligible trial comparisons (n = 1,394). Viscous fiber at a median dose of ∼13.1 g/day significantly reduced HbA1c (MD -0.58% [95% CI -0.88, -0.28]; P = 0.0002), fasting blood glucose (MD -0.82 mmol/L [95% CI -1.32, -0.31]; P = 0.001), and HOMA-insulin resistance (IR) (MD -1.89 [95% CI -3.45, -0.33]; P = 0.02) compared with control and in addition to standard of care. The certainty of evidence was graded moderate for HbA1c, fasting glucose, fasting insulin, and HOMA-IR and low for fructosamine. CONCLUSIONS: Viscous fiber supplements improve conventional markers of glycemic control beyond usual care and should be considered in the management of type 2 diabetes.
引用
- Jovanovski E, Khayyat R, Zurbau A, et al. Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2019. PMID: 30617143. doi:10.2337/dc18-1126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。